Spread of extensively resistant VIM-2-positive ST235 Ps
Kazakhstan, and Russia: a longitudinal epidemiological

Lancet Infectious Diseases, The

13, 867-876

DOI: 10.1016/s1473-3099(13)70168-3

Citation Report

#	Article	IF	Citations
1	Extensively resistant VIM-2-positive Pseudomonas aeruginosa. Lancet Infectious Diseases, The, 2013, 13, 828-829.	9.1	1
2	Pathogen-Specific Immune Fingerprints during Acute Infection: The Diagnostic Potential of Human ÃŽÂ³ÃŽÂ´ T-Cells. Frontiers in Immunology, 2014, 5, 572.	4.8	13
3	Pseudomonas aeruginosa Ceftolozane-Tazobactam Resistance Development Requires Multiple Mutations Leading to Overexpression and Structural Modification of AmpC. Antimicrobial Agents and Chemotherapy, 2014, 58, 3091-3099.	3.2	197
4	Establishment and multi drug resistance evolution of ST235 Pseudomonas aeruginosa strains in the intensive care unit of a Colombian hospital. Research in Microbiology, 2014, 165, 852-856.	2.1	9
5	Clinical and treatment-related risk factors for nosocomial colonisation with extensively drug-resistant Pseudomonas aeruginosa in a haematological patient population: a matched case control study. BMC Infectious Diseases, 2014, 14, 650.	2.9	20
6	Emergence of carbapenemases inPseudomonas aeruginosa: a worldwide problem. Expert Review of Anti-Infective Therapy, 2014, 12, 9-11.	4.4	5
7	Dissemination of IMP-6-producing Pseudomonas aeruginosa ST244 in multiple cities in China. European Journal of Clinical Microbiology and Infectious Diseases, 2014, 33, 1181-1187.	2.9	24
9	Sequence Types 235, 111, and 132 Predominate among Multidrug-Resistant Pseudomonas aeruginosa Clinical Isolates in Croatia. Antimicrobial Agents and Chemotherapy, 2014, 58, 6277-6283.	3.2	32
10	Characterization of a novel Zn2+-dependent intrinsic imipenemase from Pseudomonas aeruginosa. Journal of Antimicrobial Chemotherapy, 2014, 69, 2972-2978.	3.0	26
11	Antimicrobial activity of ceftolozane/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011â€“12). Journal of Antimicrobial Chemotherapy, 2014, 69, 2713-2722.	3.0	130
12	Emergence of carbapenemase-producing Gram-negative bacteria in Saint Petersburg, Russia. International Journal of Antimicrobial Agents, 2014, 44, 152-155.	2.5	55
13	Extensively Drug-Resistant Pseudomonas aeruginosa Isolates Containing bla _{VIM-2} and Elements of Salmonella Genomic Island 2: a New Genetic Resistance Determinant in Northeast Ohio. Antimicrobial Agents and Chemotherapy, 2014, 58, 5929-5935.	3.2	34
14	Efficacy of surface disinfectant cleaners against emerging highly resistant gram-negative bacteria. BMC Infectious Diseases, 2014, 14, 292.	2.9	22
15	Pseudomonas aeruginosa in French hospitals between 2001 and 2011: back to susceptibility. European Journal of Clinical Microbiology and Infectious Diseases, 2014, 33, 1713-1717.	2.9	13
16	Using MLST to study bacterial variation: prospects in the genomic era. Future Microbiology, 2014, 9, 623-630.	2.0	80
17	Global antibiotic consumption 2000 to 2010: an analysis of national pharmaceutical sales data. Lancet Infectious Diseases, The, 2014, 14, 742-750.	9.1	1,719
18	Aspergillomarasmine A overcomes metallo-Î²-lactamase antibiotic resistance. Nature, 2014, 510, 503-506.	27.8	461
19	Draft Genome Sequence of Colistin-Only-Susceptible Pseudomonas aeruginosa Strain ST235, a Hypervirulent High-Risk Clone in Spain. Genome Announcements, 2014, 2, .	0.8	4

#	Article	IF	Citations
20	Epidemiology and Characteristics of Metallo-Î²-Lactamase-ProducingPseudomonas aeruginosa. Infection and Chemotherapy, 2015, 47, 81.	2.3	202
21	Comparison of double-locus sequence typing (DLST) and multilocus sequence typing (MLST) for the investigation of Pseudomonas aeruginosa populations. Diagnostic Microbiology and Infectious Disease, 2015, 82, 274-277.	1.8	20
22	Pseudomonas aeruginosa: Evolution of Antimicrobial Resistance and Implications for Therapy. Seminars in Respiratory and Critical Care Medicine, 2015, 36, 044-055.	2.1	36
23	Tn 6249 , a New Tn 6162 Transposon Derivative Carrying a Double-Integron Platform and Involved with Acquisition of the bla _{VIM-1} Metallo-Î²-Lactamase Gene in Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 2015, 59, 1583-1587.	3.2	16
24	Emergence of KPC-2-Producing Pseudomonas aeruginosa Sequence Type 463 Isolates in Hangzhou, China. Antimicrobial Agents and Chemotherapy, 2015, 59, 2914-2917.	3.2	26
25	Identification of VIM-2-Producing Pseudomonas aeruginosa from Tanzania Is Associated with Sequence Types 244 and 640 and the Location of bla _{VIM-2} in a TniC Integron. Antimicrobial Agents and Chemotherapy, 2015, 59, 682-685.	3.2	26
26	Meeting the societal need for new antibiotics: the challenges for the pharmaceutical industry. British Journal of Clinical Pharmacology, 2015, 79, 168-172.	2.4	13
27	Matrix-Assisted Laser Desorption Ionizationâ€“Time of Flight Mass Spectrometry Identifies Pseudomonas aeruginosa High-Risk Clones. Journal of Clinical Microbiology, 2015, 53, 1395-1398.	3.9	51
28	Prevalence and risk factors associated with colonization and infection of extensively drug-resistantPseudomonas aeruginosa: a systematic review. Expert Review of Anti-Infective Therapy, 2015, 13, 1159-1170.	4.4	73
29	Tigecycline activity tested against carbapenem-resistant Enterobacteriaceae from 18 European nations: results from the SENTRY surveillance program (2010â€“2013). Diagnostic Microbiology and Infectious Disease, 2015, 83, 183-186.	1.8	58
30	Molecular analysis of the integrons of metallo-Î²-lactamase-producing Pseudomonas aeruginosa isolates collected by nationwide surveillance programs across Japan. BMC Microbiology, 2015, 15, 41.	3.3	36
31	Dissemination of VIM-2 producing Pseudomonas aeruginosa ST233 at tertiary care hospitals in Egypt. BMC Infectious Diseases, 2015, 15, 122.	2.9	41
32	Emerging broad-spectrum resistance in Pseudomonas aeruginosa and Acinetobacter baumannii : Mechanisms and epidemiology. International Journal of Antimicrobial Agents, 2015, 45, 568-585.	2.5	573
33	Persistence and Epidemic Propagation of a Pseudomonas aeruginosa Sequence Type 235 Clone Harboring an IS 26 Composite Transposon Carrying the bla _{IMP-1} Integron in Hiroshima, Japan, 2005 to 2012. Antimicrobial Agents and Chemotherapy, 2015, 59, 2678-2687.	3.2	14
34	Molecular surveillance for carbapenemase genes in carbapenem resistant Pseudomonas aeruginosa in Australian patients with cystic fibrosis. Pathology, 2015, 47, 156-160.	0.6	10
35	The increasing threat of Pseudomonas aeruginosa high-risk clones. Drug Resistance Updates, 2015, 21-22, 41-59.	14.4	475
36	Prevalence, antimicrobial susceptibility, and genetic diversity ofPseudomonas aeruginosaas intestinal colonizer in the community. Infectious Diseases, 2015, 47, 654-657.	2.8	7
37	Antibiotic Selection Pressure Determination through Sequence-Based Metagenomics. Antimicrobial Agents and Chemotherapy, 2015, 59, 7335-7345.	3.2	61

#	Article	IF	Citations
38	Applied Enantioselective Aminocatalysis: Î±â€Heteroatom Functionalization Reactions on the Carbapenem (Î²â€Lactam Antibiotic) Core. European Journal of Organic Chemistry, 2015, 2015, 638-646.	2.4	8
39	Influence of Virulence Genotype and Resistance Profile in the Mortality of Pseudomonas aeruginosa Bloodstream Infections. Clinical Infectious Diseases, 2015, 60, 539-548.	5.8	153
40	Faecal Carriage of Gram-Negative Multidrug-Resistant Bacteria among Patients Hospitalized in Two Centres in Ulaanbaatar, Mongolia. PLoS ONE, 2016, 11, e0168146.	2.5	9
41	Treatment satisfaction in cystic fibrosis: early patient experience with tobramycin inhalation powder. Patient Preference and Adherence, 2016, Volume 10, 2163-2169.	1.8	10
42	Applying a PCR-based open-reading frame typing method for easy genotyping and molecular epidemiological analysis of Pseudomonas aeruginosa. Journal of Applied Microbiology, 2016, 120, 487-497.	3.1	13
43	Impact of multidrug resistance on the pathogenicity of Pseudomonas aeruginosa: in vitro and in vivo studies. International Journal of Antimicrobial Agents, 2016, 47, 368-374.	2.5	30
44	Clonal Dissemination of Pseudomonas aeruginosa Sequence Type 235 Isolates Carrying bla _{IMP-6} and Emergence of bla _{GES-24} and bla _{IMP-10} on Novel Genomic Islands PAGI-15 and -16 in South Korea. Antimicrobial Agents and Chemotherapy, 2016, 60, 7216-7223.	3.2	74
45	Prevalence of Pseudomonas aeruginosa and antimicrobial-resistant Pseudomonas aeruginosa in patients with pneumonia in mainland China: a systematic review and meta-analysis. International Journal of Infectious Diseases, 2016, 49, 119-128.	3.3	65
46	In Vitro Susceptibility of Global Surveillance Isolates of Pseudomonas aeruginosa to Ceftazidime-Avibactam (INFORM 2012 to 2014). Antimicrobial Agents and Chemotherapy, 2016, 60, 4743-4749.	3.2	132
47	Nosocomial dissemination of VIM-2-producing ST235 Pseudomonas aeruginosa in Lithuania. European Journal of Clinical Microbiology and Infectious Diseases, 2016, 35, 195-200.	2.9	21
48	Prevention and control of multi-drug-resistant Gram-negative bacteria: recommendations from a Joint Working Party. Journal of Hospital Infection, 2016, 92, S1-S44.	2.9	110
49	Multiyear, Multinational Survey of the Incidence and Global Distribution of Metallo-Î²-Lactamase-Producing Enterobacteriaceae and Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 2016, 60, 1067-1078.	3.2	171
50	New mechanisms, new worries. Science, 2016, 351, 1263-1264.	12.6	44
51	Escherichia coli Overexpressing a Baeyer-Villiger Monooxygenase from Acinetobacter radioresistens Becomes Resistant to Imipenem. Antimicrobial Agents and Chemotherapy, 2016, 60, 64-74.	3.2	23
52	Structural Basis of Metallo-Î²-Lactamase Inhibition by Captopril Stereoisomers. Antimicrobial Agents and Chemotherapy, 2016, 60, 142-150.	3.2	134
53	Emergence of Imipenem-ResistantPseudomonas aeruginosaClinical Isolates from Egypt CoharboringVIMandIMPCarbapenemases. Microbial Drug Resistance, 2017, 23, 682-686.	2.0	14
54	Epidemiology and resistance characteristics of Pseudomonas aeruginosa isolates from the respiratory department of a hospital in China. Journal of Global Antimicrobial Resistance, 2017, 8, 142-147.	2.2	37
55	Antibiotic use practices of pharmacy staff: a cross-sectional study in Saint Petersburg, the Russian Federation. BMC Pharmacology & Toxicology, 2017, 18, 11.	2.4	23

#	Article	IF	Citations
56	Stenotrophomonas maltophilia healthcare-associated infections: identification of two main pathogenic genetic backgrounds. Journal of Hospital Infection, 2017, 96, 183-188.	2.9	19
57	Activity of ceftolozane/tazobactam against surveillance and â€˜problemâ€™ Enterobacteriaceae, Pseudomonas aeruginosa and non-fermenters from the British Isles. Journal of Antimicrobial Chemotherapy, 2017, 72, 2278-2289.	3.0	109
58	Emergence of Antimicrobial Resistance among Pseudomonas aeruginosa: Implications for Therapy. Seminars in Respiratory and Critical Care Medicine, 2017, 38, 326-345.	2.1	41
59	Host and Pathogen Biomarkers for Severe Pseudomonas aeruginosa Infections. Journal of Infectious Diseases, 2017, 215, S44-S51.	4.0	116
60	Molecular Characterization of Carbapenemase-Producing Pseudomonas aeruginosa of Czech Origin and Evidence for Clonal Spread of Extensively Resistant Sequence Type 357 Expressing IMP-7 Metallo-Î²-Lactamase. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	45
61	Molecular bases for multidrug resistance in Yersinia pseudotuberculosis. International Journal of Medical Microbiology, 2017, 307, 371-381.	3.6	13
62	Interplay among Resistance Profiles, High-Risk Clones, and Virulence in the Caenorhabditis elegansPseudomonas aeruginosa Infection Model. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	39
63	Genomics and Susceptibility Profiles of Extensively Drug-Resistant Pseudomonas aeruginosa Isolates from Spain. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	108
64	In Vivo Emergence of Resistance to Novel Cephalosporinâ€“Î²-Lactamase Inhibitor Combinations through the Duplication of Amino Acid D149 from OXA-2 Î²-Lactamase (OXA-539) in Sequence Type 235 Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	61
65	Surveillance of surgical site infections by Pseudomonas aeruginosa and strain characterization in Tanzanian hospitals does not provide proof for a role of hospital water plumbing systems in transmission. Antimicrobial Resistance and Infection Control, 2017, 6, 56.	4.1	16
66	Low overlap between carbapenem resistant Pseudomonas aeruginosa genotypes isolated from hospitalized patients and wastewater treatment plants. PLoS ONE, 2017, 12, e0186736.	2.5	16
67	MULTILOCUS SEQUENCE TYPING OF CARBAPENEM RESISTANT PSEUDOMONAS AERUGINOSA ISOLATES FROM PATIENTS PRESENTING AT PORT ELIZABETH HOSPITALS, SOUTH AFRICA. African Journal of Infectious Diseases, 2017, 11, 68-74.	0.9	6
68	Treatment of infections caused by multidrug-resistant Gram-negative bacteria: report of the British Society for Antimicrobial Chemotherapy/Healthcare Infection Society/British Infection Association Joint Working Partyâ€. Journal of Antimicrobial Chemotherapy, 2018, 73, iii2-iii78.	3.0	246
69	Italian nationwide survey on Pseudomonas aeruginosa from invasive infections: activity of ceftolozane/tazobactam and comparators, and molecular epidemiology of carbapenemase producers. Journal of Antimicrobial Chemotherapy, 2018, 73, 664-671.	3.0	71
70	Identification of <scp>VIM</scp>â€2 metalloâ€Î²â€lactamaseâ€producing Pseudomonas aeruginosa isolated from dogs with pyoderma and otitis in Korea. Veterinary Dermatology, 2018, 29, 186.	1.2	16
71	Carbapenemase-Producing Organisms: A Global Scourge. Clinical Infectious Diseases, 2018, 66, 1290-1297.	5.8	397
72	Global emergence of the widespread Pseudomonas aeruginosa ST235 clone. Clinical Microbiology and Infection, 2018, 24, 258-266.	6.0	138
73	Pseudomonas aeruginosa bacteremia among liver transplant recipients. Infection and Drug Resistance, 2018, Volume 11, 2345-2356.	2.7	23

#	Article	IF	Citations
74	Spread of Carbapenem Resistance by Transposition and Conjugation Among Pseudomonas aeruginosa. Frontiers in Microbiology, 2018, 9, 2057.	3.5	38
75	Ceftazidime-Avibactam Susceptibility Breakpoints against Enterobacteriaceae and Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	21
76	Characterisation of VIM-2-producing Pseudomonas aeruginosa isolates from lower tract respiratory infections in a Spanish hospital. European Journal of Clinical Microbiology and Infectious Diseases, 2018, 37, 1847-1856.	2.9	11
77	Class 1 and 2 Integrons in Hospital Strains of Gram-Negative Bacteria Isolated in Moscow and in Regions of the Russian Federation. Molecular Genetics, Microbiology and Virology, 2019, 34, 16-24.	0.3	1
78	Three Novel Class 1 Integrons Detected in Multidrug-Resistant Pseudomonas aeruginosa Hospital Strains. Molecular Genetics, Microbiology and Virology, 2019, 34, 8-15.	0.3	1
79	Evaluation of in vitro activity of ceftazidime/avibactam and ceftolozane/tazobactam against MDR Pseudomonas aeruginosa isolates from Qatar. Journal of Antimicrobial Chemotherapy, 2019, 74, 3497-3504.	3.0	24
80	Pseudomonas aeruginosa with NDM-1, DIM-1 and PME-1 Î²-lactamases, and RmtD3 16S rRNA methylase, encoded by new genomic islands. Journal of Antimicrobial Chemotherapy, 2019, 74, 3117-3119.	3.0	18
81	Spanish nationwide survey on Pseudomonas aeruginosa antimicrobial resistance mechanisms and epidemiology. Journal of Antimicrobial Chemotherapy, 2019, 74, 1825-1835.	3.0	92
82	Î²-Lactamases and Î²-Lactamase Inhibitors in the 21st Century. Journal of Molecular Biology, 2019, 431, 3472-3500.	4.2	517
83	S -Nitrosated alpha-1-acid glycoprotein exhibits antibacterial activity against multidrug-resistant bacteria strains and synergistically enhances the effect of antibiotics. FASEB BioAdvances, 2019, 1, 137-150.	2.4	2
84	Genome plasticity favours double chromosomal Tn4401b-blaKPC-2 transposon insertion in the Pseudomonas aeruginosa ST235 clone. BMC Microbiology, 2019, 19, 45.	3.3	24
85	Antimicrobial susceptibility of Pasteurella multocida isolated from sheep and pigs in Spain â€“ Short communication. Acta Veterinaria Hungarica, 2019, 67, 489-498.	0.5	12
86	Antibiotic-resistant clones in Gram-negative pathogens: presence of global clones in Korea. Journal of Microbiology, 2019, 57, 195-202.	2.8	8
87	Crystal structures of VIMâ€‘1 complexes explain active site heterogeneity in VIMâ€‘class metalloâ€Î²â€‘lactamases. FEBS Journal, 2019, 286, 169-183.	4.7	30
88	Local outbreak of extended-spectrum Î²-lactamase SHV2a-producing Pseudomonas aeruginosa reveals the emergence of a new specific sub-lineage of the international ST235 high-risk clone. Journal of Hospital Infection, 2020, 104, 33-39.	2.9	22
89	Longitudinal analysis of the in vitro activity of ceftazidime-avibactam vs. Pseudomonas aeruginosa, 2012â€“2016. Diagnostic Microbiology and Infectious Disease, 2020, 96, 114835.	1.8	12
90	VNRX-5133 (Taniborbactam), a Broad-Spectrum Inhibitor of Serine- and Metallo-Î²-Lactamases, Restores Activity of Cefepime in Enterobacterales and Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	123
91	Secondary in-hospital epidemiological investigation after an outbreak of Pseudomonas aeruginosa ST357. Journal of Infection and Chemotherapy, 2020, 26, 257-265.	1.7	7

#	Article	IF	Citations
92	Agents of Last Resort. Infectious Disease Clinics of North America, 2020, 34, 723-750.	5.1	22
93	Metallo-Î²-Lactamases: Structure, Function, Epidemiology, Treatment Options, and the Development Pipeline. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	127
94	Metallo-ÃŸ-lactamases: a review. Molecular Biology Reports, 2020, 47, 6281-6294.	2.3	64
95	Unravelling the Features of Success of VIM-Producing ST111 and ST235 Pseudomonas aeruginosa in a Greek Hospital. Microorganisms, 2020, 8, 1884.	3.6	13
96	Phenotypic and Genomic Comparison of the Two Most Common ExoU-Positive Pseudomonas aeruginosa Clones, PA14 and ST235. MSystems, 2020, 5, .	3.8	19
97	Determination of carbapenems in water samples by UHPLCâ€“MS/MS. Journal of Separation Science, 2020, 43, 2321-2329.	2.5	5
98	Longitudinal analysis of ESBL and carbapenemase carriage among Enterobacterales and Pseudomonas aeruginosa isolates collected in Europe as part of the International Network for Optimal Resistance Monitoring (INFORM) global surveillance programme, 2013â€“17. Journal of Antimicrobial Chemotherapy, 2020, 75, 1165-1173.	3.0	49
99	Genotypes, carbapenemase carriage, integron diversity and oprD alterations among carbapenem-resistant Pseudomonas aeruginosa from Russia. International Journal of Antimicrobial Agents, 2020, 55, 105899.	2.5	13
100	4-Amino-1,2,4-triazole-3-thione as a Promising Scaffold for the Inhibition of Serine and Metallo-Î²-Lactamases. Pharmaceuticals, 2020, 13, 52.	3.8	13
101	Genetic Characterization of Carbapenemase-Producing Enterobacter cloacae Complex and Pseudomonas aeruginosa of Food of Animal Origin from Egypt. Microbial Drug Resistance, 2021, 27, 196-203.	2.0	14
102	Diversity and Distribution of Resistance Markers in Pseudomonas aeruginosa International High-Risk Clones. Microorganisms, 2021, 9, 359.	3.6	24
103	Mobile Carbapenemase Genes in Pseudomonas aeruginosa. Frontiers in Microbiology, 2021, 12, 614058.	3.5	95
104	AMRmap: An Interactive Web Platform for Analysis of Antimicrobial Resistance Surveillance Data in Russia. Frontiers in Microbiology, 2021, 12, 620002.	3.5	26
105	Activity of cefepime/zidebactam (WCK 5222) against â€˜problemâ€™ antibiotic-resistant Gram-negative bacteria sent to a national reference laboratory. Journal of Antimicrobial Chemotherapy, 2021, 76, 1511-1522.	3.0	17
106	How to kill Pseudomonasâ€”emerging therapies for a challenging pathogen. Annals of the New York Academy of Sciences, 2021, 1496, 59-81.	3.8	15
107	Antimicrobial Susceptibility Profiles To Predict the Presence of Carbapenemase Genes among Carbapenem-Resistant Pseudomonas aeruginosa Isolates. Journal of Clinical Microbiology, 2021, 59, .	3.9	9
108	Genomic surveillance of Pseudomonas aeruginosa in the Philippines, 2013â€“2014. Western Pacific Surveillance and Response Journal: WPSAR, 2021, 12, 4-18.	0.6	3
109	Molecular and genomic epidemiology of VIM/IMP-like metallo-Î²-lactamase-producing Pseudomonas aeruginosa genotypes in Poland. Journal of Antimicrobial Chemotherapy, 2021, 76, 2273-2284.	3.0	8

#	Article	IF	Citations
110	Antimicrobial Resistance and Type III Secretion System Virulotypes of Pseudomonas aeruginosa Isolates from Dogs and Cats in Primary Veterinary Hospitals in Japan: Identification of the International High-Risk Clone Sequence Type 235. Microbiology Spectrum, 2021, 9, e0040821.	3.0	9
111	Biomaterial-based antimicrobial therapies for the treatment of bacterial infections. Nature Reviews Materials, 2022, 7, 39-54.	48.7	184
112	Molecular epidemiology of Pseudomonas aeruginosa bloodstream infection isolates in a non-outbreak setting. Journal of Medical Microbiology, 2017, 66, 154-159.	1.8	8
113	Identification of carbapenem-resistant Pseudomonas aeruginosa in selected hospitals of the Gulf Cooperation Council States: dominance of high-risk clones in the region. Journal of Medical Microbiology, 2018, 67, 846-853.	1.8	44
114	Acquired qnrVC1 and bla NDM-1 resistance markers in an international high-risk Pseudomonas aeruginosa ST773 clone. Journal of Medical Microbiology, 2019, 68, 336-338.	1.8	23
116	Antibiotic treatmentâ€“induced secondary IgA deficiency enhances susceptibility to Pseudomonas aeruginosa pneumonia. Journal of Clinical Investigation, 2018, 128, 3535-3545.	8.2	75
117	Population Structure of Clinical Pseudomonas aeruginosa from West and Central African Countries. PLoS ONE, 2014, 9, e107008.	2.5	23
118	Crystal Structure of DIM-1, an Acquired Subclass B1 Metallo-Î²-Lactamase from Pseudomonas stutzeri. PLoS ONE, 2015, 10, e0140059.	2.5	3
119	Notes from the Field: Verona Integron-Encoded Metallo-Beta-Lactamaseâ€“Producing Pseudomonas aeruginosa Outbreak in a Long-Term Acute Care Hospital â€” Orange County, Florida, 2017. Morbidity and Mortality Weekly Report, 2018, 67, 611-612.	15.1	9
120	Ð¡ARBAPENEMASE-PRODUCING GRAM-NEGATIVE BACTERIA IN A SPECIALIZED HOSPITAL OF ST. PETERSBURG. Russian Journal of Infection and Immunity, 2017, 7, 181-192.	0.7	2
121	Isolation of NDM-1-producing Pseudomonas aeruginosa sequence type ST235 from a stem cell transplant patient in Italy, May 2013. Eurosurveillance, 2013, 18, .	7.0	31
123	Sensitivity to Antimicrobial Drugs of Pseudomonas Aeruginosa Extreme-Resistant Strains Isolated in the Major Hospitals of Central Kazakhstan. Open Access Macedonian Journal of Medical Sciences, 2017, 5, 6-8.	0.2	1
124	Problematic Groups of Multidrug-Resistant Bacteria and Their Resistance Mechanisms. , 2019, , 25-69.		1
125	Three novel class 1 integrons detected in multi drug resistant hospital strains. Molekuliarnaia Genetika, Mikrobiologiia I Virusologiia, 2019, 37, 9.	0.4	1
126	Class 1 and class 2 integrons in hospital strains of gramnegative bacteria isolated in Moscow and other regions of the Russian Federation. Molekuliarnaia Genetika, Mikrobiologiia I Virusologiia, 2019, 37, 17.	0.4	2
127	CRISPR Element Patterns vs. Pathoadaptability of Clinical Pseudomonas aeruginosa Isolates from a Medical Center in Moscow, Russia. Antibiotics, 2021, 10, 1301.	3.7	2
130	Pseudomonas aeruginosa Pneumonia: Evolution of Antimicrobial Resistance and Implications for Therapy. Seminars in Respiratory and Critical Care Medicine, 2022, 43, 191-218.	2.1	7
131	Bacteriophageâ€Loaded Poly(lacticâ€coâ€glycolic acid) Microparticles Mitigate Staphylococcus aureus Infection and Cocultures of Staphylococcus aureus and Pseudomonas aeruginosa. Advanced Healthcare Materials, 2022, 11, e2102539.	7.6	8

#	Article	IF	Citations
132	Extensively Drug-Resistant Carbapenemase-Producing Pseudomonas aeruginosa and Medical Tourism from the United States to Mexico, 2018â€“2019. Emerging Infectious Diseases, 2022, 28, 52-62.	4.3	9
133	Evaluation of Blood-Brain-Barrier Permeability, Neurotoxicity, and Potential Cognitive Impairment by Pseudomonas aeruginosaâ€™s Virulence Factor Pyocyanin. Oxidative Medicine and Cellular Longevity, 2022, 2022, 1-14.	4.0	4
134	Empiric Treatment in HAP/VAP: â€œDonâ€™t You Want to Take a Leap of Faith?â€• Antibiotics, 2022, 11, 359.	3.7	8
135	Discovery of a Potent Inhibitor to Overcome Carbapenem Resistance in Pseudomonas aeruginosa Strains via Inhibition of VIM-2 Metallo-Î²-lactamases. , 2022, In Press, .		0
140	Systemic evaluation of antibacterial activity of Anacardium occidentale. The Journal of Phytopharmacology, 2014, 3, 193-199.	0.3	5
141	The primary pharmacology of ceftazidime/avibactam: in vitro translational biology. Journal of Antimicrobial Chemotherapy, 2022, 77, 2321-2340.	3.0	4
142	Prevalence and microbiological and genetic characteristics of multidrug-resistant Pseudomonas aeruginosa over three years in Qatar. Antimicrobial Stewardship & Healthcare Epidemiology, 2022, 2, .	0.5	6
143	Characterization of <i>Pseudomonas aeruginosa</i> isolated from positive samples of hemocultures and cerebrospinal fluid of children. Zhurnal Mikrobiologii Epidemiologii I Immunobiologii, 2022, 99, 309-321.	1.0	2
144	The primary pharmacology of ceftazidime/avibactam: resistancein vitro. Journal of Antimicrobial Chemotherapy, 2023, 78, 569-585.	3.0	5
145	Insight into phylogenomic bias of bla or bla dissemination amongst carbapenem-resistant Pseudomonas aeruginosa. International Journal of Antimicrobial Agents, 2023, 61, 106788.	2.5	6
146	Incidence of ESBLs and carbapenemases among Enterobacterales and carbapenemases in Pseudomonas aeruginosa isolates collected globally: results from ATLAS 2017â€“2019. Journal of Antimicrobial Chemotherapy, 2023, 78, 1606-1615.	3.0	5
147	Spread of multidrug-resistant Pseudomonas aeruginosa in animal-derived foods in Beijing, China. International Journal of Food Microbiology, 2023, 403, 110296.	4.7	5
148	In vitro activity of cefiderocol against MBL-producing Gram-negative bacteria collected in North America and Europe in five consecutive annual multinational SIDERO-WT surveillance studies (2014â€“2019). Journal of Antimicrobial Chemotherapy, 2023, 78, 2019-2027.	3.0	7
149	Case Commentary: Successful Use of Cefepime/Zidebactam (WCK 5222) as a Salvage Therapy for the Treatment of Disseminated Extensively Drug-Resistant New Delhi Metallo-Î²-Lactamase-Producing Pseudomonas aeruginosa Infection in an Adult Patient with Acute T-Cell Leukemia. Antimicrobial Agents and Chemotherapy, 0, . .	3.2	1
150	The Prevalence of Metallo-Beta-Lactamese-(MÎ²L)-Producing Pseudomonas aeruginosa Isolates in Brazil: A Systematic Review and Meta-Analysis. Microorganisms, 2023, 11, 2366.	3.6	0
151	Pseudomonas aeruginosa antibiotic susceptibility profiles, genomic epidemiology and resistance mechanisms: a nation-wide five-year time lapse analysis. Lancet Regional Health - Europe, The, 2023, 34, 100736.	5.6	3
152	Extensively Drug-Resistant Pseudomonas aeruginosa Outbreak Associated With Artificial Tears. Clinical Infectious Diseases, 0, , .	5.8	0
153	Detection of bla-AIM Metallo Beta Lactamase Gene among Stenotrophomonas Maltophilia and Carbapenem Resistant Pseudomonas Aeruginosa Isolated from Various Infections in AL- Najaf Province. Revista Bionatura, 2024, 9, 1-7.	0.4	0